

CITATION REPORT

List of articles citing

Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ^9 -THC: mechanism underlying greater toxicity?

DOI: 10.1016/j.lfs.2013.09.017
Life Sciences, 2014, 97, 45-54.

Source: <https://exaly.com/paper-pdf/58987092/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
217	Δoids in a nutshell: everything you (don't) want to know about synthetic cannabimimetics. 2014 , 7, 137-148		18
216	Synthetic Marijuana: A Recent Turmoil in Substance Abuse. 2014 , 24, 396-404		4
215	Method validation of the biochip array technology for synthetic cannabinoids detection in urine. 2014 , 6, 2919-30		14
214	Baths salts, spice, and related designer drugs: the science behind the headlines. 2014 , 34, 15150-8		111
213	Acute kidney injury associated with smoking synthetic cannabinoid. 2014 , 52, 664-73		82
212	Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates. 2014 , 143, 268-71		96
211	Neuronal substrates and functional consequences of prenatal cannabis exposure. 2014 , 23, 931-41		76
210	XLR-11 and UR-144 in Washington state and state of Alaska driving cases. 2014 , 38, 563-8		21
209	Sudden cardiac death complicating acute myocardial infarction following synthetic cannabinoid use. 2014 , 44, 934-6		17
208	Quantitative measurement of XLR11 and UR-144 in oral fluid by LC-MS-MS. 2014 , 38, 315-21		23
207	Understanding the risks associated with the use of new psychoactive substances (NPS): high variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products. 2014 , 229, 220-8		44
206	Δ-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market. 2015 , 26, 460-8		38
205	Frequency of Synthetic Cannabinoid Use and Its Relationship with Socio-Demographic Characteristics and Treatment Outcomes in Alcohol-and Substance-Dependent Inpatients: A retrospective study. 2015 , 25, 348-354		44
204	Rhabdomyolysis and Acute Kidney Injury Requiring Dialysis as a Result of Concomitant Use of Atypical Neuroleptics and Synthetic Cannabinoids. 2015 , 2015, 235982		16
203	Synthetic Cannabinoids. 2015 , 350, 59-62		106
202	Legal highs: staying on top of the flood of novel psychoactive substances. 2015 , 5, 97-132		114
201	JWH-018 impairs sensorimotor functions in mice. 2015 , 300, 174-88		41

200	K2 types and their contents: are product disclosures true?. 2015 , 33, 845-6	4
199	Pharmacology and toxicology of the synthetic cannabinoid receptor agonists. 2015 , 24, 527-541	6
198	Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice. 2015 , 150, 31-7	15
197	Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. 2015 , 6, 1445-58	138
196	Novel halogenated derivatives of JWH-018: Behavioral and binding studies in mice. 2015 , 95, 68-82	60
195	Cannabis: the never-ending, nefarious nepenthe of the 21st century: what should the clinician know?. 2015 , 61, 118-75	10
194	"Legal Highs"--An Emerging Epidemic of Novel Psychoactive Substances. 2015 , 120, 273-300	35
193	Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018. 2015 , 97, 562-4	24
192	New Drugs of Abuse and Withdrawal Syndromes. 2015 , 33, 779-95	16
191	Application of a validated LC-MS/MS method for JWH-073 and its metabolites in blood and urine in real forensic cases. 2015 , 257, 165-171	15
190	Next generation of novel psychoactive substances on the horizon - A complex problem to face. 2015 , 157, 1-17	124
189	High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS. 2015 , 129, 1233-45	28
188	Repeated administration of phytocannabinoid (Δ^9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. 2015 , 102, 22-32	31
187	Stimulation of <i>in vivo</i> dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid. 2015 , 99, 705-14	54
186	Bioisosteric Fluorine in the Clandestine Design of Synthetic Cannabinoids. 2015 , 68, 4	26
185	Cannabinoïdes de synthèse : aspects pharmacologiques. 2015 , 27, 23-32	2
184	Synthetic Cannabinoids: Use and Predictors in a Community Sample of Young Adults. 2015 , 36, 368-73	73
183	Toxicology and management of novel psychoactive drugs. 2015 , 28, 50-65	63

182	Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. 2016 , 11, e0167240	10
181	Four analytically confirmed cases of use of third-generation synthetic cannabinoid receptor agonists incorporating an adamantyl group. 2016 , 54, 533-4	2
180	Development of a mass spectrometric hydroxyl-position determination method for the hydroxyindole metabolites of JWH-018 by GC-MS/MS. 2016 , 51, 350-7	7
179	Synthetic cannabinoid JWH-018 and its halogenated derivatives JWH-018-Cl and JWH-018-Br impair Novel Object Recognition in mice: Behavioral, electrophysiological and neurochemical evidence. 2016 , 109, 254-269	22
178	"Just one bad high:" considering synthetic cannabinoid outcome expectancies in adolescents. 2016 , 25, 620-622	
177	Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. 2016 , 18, 52	155
176	Screening new psychoactive substances in urban wastewater using high resolution mass spectrometry. 2016 , 408, 4297-309	37
175	Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service. 2016 , 54, 512-8	41
174	Screening Medications for the Treatment of Cannabis Use Disorder. 2016 , 126, 87-120	12
173	Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. 2016 , 30, 1321-1330	57
172	Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of <i>in vivo</i> assays in mice. 2016 , 110, 143-153	32
171	Novel Drugs of Abuse: Cannabinoids, Stimulants, and Hallucinogens. 2016 , 893-902	3
170	Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay. 2016 , 88, 11476-11485	142
169	NPS: Medical Consequences Associated with Their Intake. 2017 , 32, 351-380	21
168	Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. 2016 , 9, 943-54	34
167	1-Adamantylamine a simple urine marker for screening for third generation adamantyl-type synthetic cannabinoids by ultra-performance liquid chromatography tandem mass spectrometry. 2016 , 53, 640-646	7
166	Effect of JWH-250, JWH-073 and their interaction on "tetrad", sensorimotor, neurological and neurochemical responses in mice. 2016 , 67, 31-50	48
165	Reply to 'Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA'. 2016 , 40, 240-2	27

164	Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice. 2016 , 58, 15-22	31
163	Biotransformation of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by <i>Cunninghamella elegans</i> . 2016 , 261, 33-42	28
162	What Can a Urine Drug Screening Immunoassay Really Tell Us?. 2016 , 29, 516-26	18
161	User Experiences of Development of Dependence on the Synthetic Cannabinoids, 5F-AKB48 and 5F-PB-22, and Subsequent Withdrawal Syndromes. 2017 , 15, 565-579	23
160	Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ^9 -tetrahydrocannabinol. 2017 , 22, 390-399	22
159	[Synthetic cannabinoids: A new addiction matrix]. 2017 , 46, 11-22	8
158	Synthetic Pot: Not Your Grandfather's Marijuana. 2017 , 38, 257-276	60
157	Cannabinoids as hippocampal network administrators. 2017 , 124, 25-37	37
156	Mechanisms contributing to cognitive deficits in cannabis users. 2017 , 124, 84-88	16
155	Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by <i>Cunninghamella elegans</i> . 2017 , 19, 1148-1162	17
154	Clinical and financial implications of emergency department visits for synthetic marijuana. 2017 , 35, 1506-1509	9
153	Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA. 2017 , 8, 1673-1680	31
152	The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre. 2017 , 43, 74-82	12
151	Measuring biomarkers in wastewater as a new source of epidemiological information: Current state and future perspectives. 2017 , 99, 131-150	141
150	Synthetic cannabinoids: A review of the clinical implications of a new drug of choice. 2017 , 30, 1-4	7
149	Novel Psychoactive Substances and Trends of Abuse. 2017 , 40, 374-382	10
148	Characterization of structurally novel G protein biased CB agonists: Implications for drug development. 2017 , 125, 161-177	25
147	Synthetic Cannabinoids Use in Elderly Patients. 2017 , 23, 230-232	4

146	Synthetic cannabinoid induced acute respiratory depression: Case series and literature review. 2017 , 22, 137-141	24
145	Synthetic cannabinoids: the hidden side of Spice drugs. 2017 , 28, 409-419	55
144	Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis. 2017 , 14, 9	18
143	Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project. 2017 , 13, 52-60	54
142	Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health. 2017 , 8, 156	124
141	Spice-y Kidney Failure: A Case Report and Systematic Review of Acute Kidney Injury Attributable to the Use of Synthetic Cannabis. 2017 , 21,	34
140	Accidents and Synthetic Cannabinoids in Blood of Drivers. 2017 , 848-855	
139	Preface to DMR special edition 'Cannabinoid receptors and ligands: therapeutic drug development and abuse potential'. 2018 , 50, 1-2	7
138	Bioanalytical Methods for New Psychoactive Substances. 2018 , 252, 413-439	28
137	Synthetic Cannabinoids and Synthetic Cannabinoid-Induced Psychotic Disorders. 2018 , 199-220	3
136	Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. 2018 , 498, 597-602	19
135	Intoxication by the synthetic cannabinoid 5-fluoro-ABD, acquired as ketamine. 2018 , 151, 168	2
134	Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. 2018 , 365, 437-446	48
133	Synthetic cannabinoid use in an acute psychiatric inpatient unit. 2018 , 27, 600-607	7
132	Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073. 2018 , 134, 92-100	5
131	Broad and Region-Specific Impacts of the Synthetic Cannabinoid CP 55,940 in Adolescent and Adult Female Mouse Brains. 2018 , 11, 436	2
130	The Changing Face of Synthetic Cannabinoids in Texas. 2018 , 50, 281-286	4
129	Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ ⁹ THC. 2018 , 9, 1084	14

128	Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. 2018 , 192, 285-293		4
127	Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches. 2018 , 30, 277-284		29
126	Association between synthetic cannabinoid use and depressive symptomology: Analysis of a US national survey of high-school seniors. 2018 , 23, 113-119		
125	Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. <i>Addiction</i> , 2018 , 113, 1850-1861	4.6	5
124	New and Emerging Illicit Psychoactive Substances. 2018 , 102, 697-714		25
123	Intoxication by the synthetic cannabinoid 5-fluoro-ABD, acquired as ketamine. 2018 , 151, 168		
122	Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. 2018 , 6, 162		70
121	Synthetic cannabinoids: Variety is definitely not the spice of life. 2018 , 59, 36-38		9
120	In vitro determination of the efficacy of illicit synthetic cannabinoids at CB receptors. 2019 , 176, 4653-4665		25
119	New psychoactive substances: challenges for drug surveillance, control, and public health responses. 2019 , 394, 1668-1684		100
118	Identification of synthetic cannabinoids that were seized, consumed, or associated with deaths in Kuwait in 2018 using GC-MS and LC-MS-MS analysis. 2019 , 303, 109960		19
117	Synthetic cannabinoid use disorder: an update for general psychiatrists. 2019 , 27, 279-283		12
116	Activity-based reporter assays for the screening of abused substances in biological matrices. 2019 , 49, 95-109		11
115	The effects of alcohol and cannabinoid exposure during the brain growth spurt on behavioral development in rats. 2019 , 111, 760-774		19
114	Review of the many faces of synthetic cannabinoid toxicities. 2019 , 9, 93-99		34
113	Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors. 2019 , 368, 414-422		23
112	Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids. 2019 , 70, 72-79		18
111	Synthetic Cannabinoid Use. 2019 , 169-176		1

110	Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex. 2019 , 176, 448-458.e12	196
109	Cannabinoid exposure during pregnancy and its impact on immune function. 2019 , 76, 729-743	22
108	Suspect and non-target screening workflows to investigate the in vitro and in vivo metabolism of the synthetic cannabinoid 5Cl-THJ-018. 2019 , 11, 479-491	15
107	Synthetic marijuana is no more marijuana. 2019 , 43, 211-212	2
106	Functional effects of synthetic cannabinoids versus Δ^9 THC in mice on body temperature, nociceptive threshold, anxiety, cognition, locomotor/exploratory parameters and depression. 2019 , 24, 414-425	12
105	Synthetic cannabinoid receptor agonists: classification and nomenclature. 2020 , 58, 82-98	37
104	Synthetic Cannabinoids (SCs) in Metaphors: a Metaphorical Analysis of User Experiences of Synthetic Cannabinoids in Two Countries. 2020 , 18, 160-176	2
103	Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists. 2020 , 12, 297-315	10
102	DARK Classics in Chemical Neuroscience: Synthetic Cannabinoids (Spice/K2). 2019 ,	9
101	Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. 2020 , 199, 173059	13
100	Foreword. 2020 , xii-xiv	
99	Concepts of Addiction. 2020 , 1-50	
98	Appetitive Needs and Addiction. 2020 , 3-11	8
97	Behavioral Economics and Addictive Disorders. 2020 , 12-22	40
96	Sensitization of Incentive Salience and the Transition to Addiction. 2020 , 23-37	40
95	Philosophical Issues in the Addictions. 2020 , 38-50	
94	Clinical and Research Methods in the Addictions. 2020 , 51-118	
93	Human Neurobiological Approaches to Hedonically Motivated Behaviors. 2020 , 53-61	40

92	Human Laboratory Paradigms in Addictions Research. 2020 , 62-72	
91	Behavioral Economic Considerations of Novel Addictions and Nonaddictive Behavior: Research and Analytic Methods. 2020 , 73-86	40
90	Substance and Behavioral Addictions Assessment Instruments. 2020 , 87-105	1
89	Qualitative Approaches to the Study of Substance and Behavioral Addictions. 2020 , 106-118	1
88	Levels of Analysis and Etiology. 2020 , 119-198	
87	Neurobiology of Substance Addictions. 2020 , 121-135	40
86	Neurobiological Foundations of Behavioral Addictions. 2020 , 136-151	40
85	Multiple Memory Systems, Addiction, and Health Habits: New Routes for Translational Science. 2020 , 152-170	40
84	The Role of Culture in Addiction. 2020 , 171-181	2
83	The Physical and Social Environments as Determinants of Health: Implications for Substance and Behavioral Addictions. 2020 , 182-198	
82	Prevention and Treatment. 2020 , 199-294	
81	Adolescent Drug Misuse Prevention: Challenges in School-Based Programming. 2020 , 201-214	1
80	Treatment of Alcohol, Tobacco, and Other Drug (ATOD) Misuse. 2020 , 215-229	2
79	Prevention and Treatment of Food Addiction 2020 , 230-240	40
78	The Prevention and Treatment of Gambling Disorders: Some Art, Some Science. 2020 , 241-253	42
77	Prevention and Treatment of Sex Addiction. 2020 , 254-261	1
76	Passionate Love Addiction: An Evolutionary Survival Mechanism That Can Go Terribly Wrong. 2020 , 262-270	
75	Prevention and Treatment of Compulsive Buying Disorder. 2020 , 271-279	40

74	Prevention and Treatment of Work Addiction. 2020 , 280-287	
73	Gaming Disorder and Its Treatment. 2020 , 288-294	1
72	Ongoing and Future Research Directions. 2020 , 295-425	
71	Precision Behavioral Management (PBM): A Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS) Relevant to the Opiate Crisis. 2020 , 297-306	40
70	Novel Psychoactive Substances: A New Challenge for Prevention and Treatment. 2020 , 307-325	
69	Impaired Physicians. 2020 , 326-332	
68	Feedback Models for Gambling Control: The Use and Efficacy of Online Responsible Gambling Tools. 2020 , 333-339	40
67	Food versus Eating Addictions. 2020 , 340-351	40
66	Measurement, Prevention, and Treatment of Exercise Addiction. 2020 , 352-361	
65	Tanning as an Addiction: The State of the Research and Implications for Intervention. 2020 , 362-372	40
64	Considering the Overlap and Nonoverlap of Compulsivity, Impulsivity, and Addiction. 2020 , 373-385	41
63	Anhedonia in Addictive Behaviors. 2020 , 386-408	
62	Mindfulness-Based Interventions Applied to Addiction Treatments. 2020 , 409-417	40
61	American Legal Issues in Addiction Treatment and Research. 2020 , 418-425	
60	Index. 2020 , 426-446	
59	Appendix B: Metabolism of Major Illicit Drugs. 2020 , 571-625	
58	Δ ⁹ -Tetrahydrocannabinol: Drug discrimination abuse liability testing in female Lister Hooded rats: Trials, tribulations and triumphs. 2020 , 106, 106937	1
57	The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice. 2020 , 214, 108179	2

56	Chronic Use of Synthetic Cannabinoids Is Associated With Impairment in Working Memory and Mental Flexibility. 2020 , 11, 602	9
55	Neurochemical and Behavioral Characterization after Acute and Repeated Exposure to Novel Synthetic Cannabinoid Agonist 5-MDMB-PICA. 2020 , 10,	2
54	Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation. 2021 , 53, 207-214	
53	New psychoactive substances: a review and updates. 2020 , 10, 2045125320967197	36
52	In vitro activity profiling of Cumyl-PEGACLONE variants at the CB receptor: Fluorination versus isomer exploration. 2020 , 12, 1336-1343	10
51	The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. 2020 , 50, 359-382	32
50	Personality Traits and Psychotic Proneness Among Chronic Synthetic Cannabinoid Users. 2020 , 11, 355	5
49	Post-Mortem Toxicology: A Systematic Review of Death Cases Involving Synthetic Cannabinoid Receptor Agonists. 2020 , 11, 464	31
48	The impact of legislation on acute synthetic cannabinoid harms resulting in ambulance attendance. 2020 , 79, 102720	3
47	Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. 2020 , 175, 113871	15
46	Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). 2020 , 8, e00561	1
45	The use of synthetic cannabinoid receptor agonists (SCRAs) within the homeless population: motivations, harms and the implications for developing an appropriate response. 2021 , 29, 1-10	14
44	Sex-dependent pharmacological profiles of the synthetic cannabinoid MMB-Fubinaca. 2021 , 26, e12940	1
43	Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists. 2021 , 78, 109865	11
42	Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis. 2021 , 1	3
41	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB receptor activation assays-Part II: Structure activity relationship assessment via a β -arrestin recruitment assay. 2021 , 13, 1402-1411	5
40	Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications. 2021 , 11,	2
39	Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor. 2021 , 11, 10611	6

38	Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings. 2021 , 157, 1674-1696	5
37	Abuse Potential of Synthetic Cannabinoids: AM-1248, CB-13, and PB-22. 2021 , 29, 384-391	3
36	Phase I In Vitro Metabolic Profiling of the Synthetic Cannabinoid Receptor Agonists CUMYL-THPINACA and ADAMANTYL-THPINACA. 2021 , 11,	0
35	The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients. 2021 , 3, 33	
34	Rapid screening of 23 synthetic cannabinoids in blood by direct analysis in real time - Tandem mass spectrometry. 2021 , 469, 116667	2
33	'Synthetic cannabis': A dangerous misnomer. 2021 , 98, 103396	2
32	Substance Use Disorders: Cognitive Sequelae, Behavioral Manifestations, Neuroimaging Correlates, and Novel Interventions. 2019 , 697-728	2
31	New Drugs of Abuse and Cardiovascular Function. 2020 , 843-868	2
30	Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples. 2021 , 39, 198-212	5
29	The Cambridge Handbook of Substance and Behavioral Addictions. 2020 ,	44
28	In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids.	2
27	A Curious Case of Inhalation Fever Caused by Synthetic Cannabinoid. <i>American Journal of Case Reports</i> , 2016 , 17, 379-83	1-3 5
26	Cannabis, cannabinoids, and health. 2017 , 19, 309-316	83
25	Assessment of the Abuse Liability of Synthetic Cannabinoid Agonists JWH-030, JWH-175, and JWH-176. 2015 , 23, 590-6	14
24	Theta and Alpha Oscillatory Activity During Working Memory Maintenance in Long-Term Cannabis Users: The Importance of the Polydrug Use Context. 2021 , 15, 740277	1
23	NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?. 2021 , 12, 4020-4036	0
22	Indole Hallucinogens. 2016 , 1-22	0
21	Hallucinogens. 2017 , 1587-1607	

20	Analysis of Deaths Related to Synthetic Cannabinoid (Bonsai) in Eskişehir, Turkey. 1459-1469		
19	Preface. 2020, xv-xvii		
18	Toxicologie des Cathinones «Sels de bain». 2020, 32, 142-150		
17	New Drugs of Abuse and Cardiovascular Function. 2020, 1-27		
16	The Changing Face of Recreational Drug Use. <i>Cerebrum: the Dana Forum on Brain Science</i> , 2016, 2016,	0	4
15	Designer Drugs. 2022, 185-194		
14	Considerations for Cannabinoids in Perioperative Care by Anesthesiologists.. <i>Journal of Clinical Medicine</i> , 2022, 11,	5.1	3
13	Future Therapeutic Potential of Synthetic Cannabinoids and Endocannabinoid System Modulators. 2022, 91-115		
12	Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis.. <i>Molecular Biology Reports</i> , 2022, 1	2.8	0
11	A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES).. <i>American Journal of Case Reports</i> , 2022, 23, e936209	1.3	
10	Effects of Δ -Tetrahydrocannabinol (THC) on Obesity at Different Stages of Life: A Literature Review.. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19,	4.6	0
9	Table_1.DOCX. 2018,		
8	Table_1.DOCX. 2018,		
7	Epigenetic Studies for Evaluation of NPS Toxicity: Focus on Synthetic Cannabinoids and Cathinones. <i>Biomedicines</i> , 2022, 10, 1398	4.8	0
6	Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act. <i>Addiction</i> ,	4.6	1
5	Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice.		
4	Metabolism of ADB-4en-PINACA in Zebrafish and Rat Liver Microsomes Determined by Liquid Chromatography-High Resolution Mass Spectrometry. 2022, 77, 1036-1046		
3	In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists. 2022, 220, 173467		0

- 2 Common street drug names for the anesthesiologist and pain physician. rapm-2022-104189
- 1 Non-targeted screen based on EI-MS spectra using statistical methods: An investigative study of synthetic indole/indazole cannabinoids.